A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2124

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation
Percutaneous Coronary Intervention

Interventions

DRUG: rivaroxaban 2.5 mg
DRUG: rivaroxaban 15 mg
DRUG: rivaroxaban 10 mg
DRUG: aspirin (ASA)
DRUG: vitamin K antagonist (VKA)
DRUG: clopidogrel
DRUG: prasugrel
DRUG: ticagrelor

Sponsor

Janssen Scientific Affairs, LLC

Collaborators

[object Object]